The Different Pro-angiogenesis Ability Of BM-MSCs In Multiple Myeloma In Active And Remissive State

Objective: To investigate the difference in the pro-angiogenesis ability of bone marrow mesenchymal stem cells in multiple myeloma in active and remissive state, providing a theoretical basis for exploring the treatment of multiple myeloma Methords: 1. Bone marrow samples derived from 13 newly diagnosed multiple myeloma patients before and after four therapeutic cycles were extracted to isolate and culture bone marrow mesenchymal stem cells. 2. The ELISA assay was used to detect the density of vascular endothelial growth factor(VEGF), hepatocyte growth factor(HGF) and basic fibroblast growth factor(b FGF) in the supernatant of bone marrow mesenchymal stem cells(BM-MSCs) of myeloma patients. 3. The proliferative ability and movement of human umbilical vein endothelial cells(HUVECs) cultured in the supernatant of bone marrow mesenchymal stem cells were detected by MTT assay and Transwell assay, respectively. 4. The tube formation exprement in vitro was used to measure the pro-angiogenesis ability of bone marrow mesenchymal stem cells of myeloma patients. 5. All experiments were repeated three times in the form of x_ ± s. The univariate analysis of variance(ANOVA) was used to analyze the mean of multiple samples, and the t- test was used to analyze the difference between two groups. Two-sided test and P <0.05 was considered statistically significant. Results: 1. The concentration of VEGF, HGF and b FGF in the cell supernatant of BM-MSCs in active myeloma was significantly higher than that in remissive myeloma(P < 0.05). 2. The supernatant of BM-MSCs of active myeloma more significantly promoted the proliferation of HUVECs(P <0.05).3. The supernatant of BM-MSCs from patients with active myeloma had greater ability to promote the HUVECs migration than with the remissive(P <0.05). 4. The pro-angiogenesis ability of BM-MSCs and the supernatant from active myeloma was significantly stronger than that in the remission in vitro(P <0.05). Conclusion: The findings indicated that the BM-MSCs from active myeloma had stronger pro-angiogenesis ability than that from remissive myeloma.